169 related articles for article (PubMed ID: 30864675)
21. Compensatory RNA polymerase 2 loading determines the efficacy and transcriptional selectivity of JQ1 in Myc-driven tumors.
Donato E; Croci O; Sabò A; Muller H; Morelli MJ; Pelizzola M; Campaner S
Leukemia; 2017 Feb; 31(2):479-490. PubMed ID: 27443262
[TBL] [Abstract][Full Text] [Related]
22. Aberrant expression of cancer stem cell markers (CD44, CD90, and CD133) contributes to disease progression and reduced survival in hepatoblastoma patients: 4-year survival data.
Bahnassy AA; Fawzy M; El-Wakil M; Zekri AR; Abdel-Sayed A; Sheta M
Transl Res; 2015 Mar; 165(3):396-406. PubMed ID: 25168019
[TBL] [Abstract][Full Text] [Related]
23. Blocking the hedgehog pathway inhibits hepatoblastoma growth.
Eichenmüller M; Gruner I; Hagl B; Häberle B; Müller-Höcker J; von Schweinitz D; Kappler R
Hepatology; 2009 Feb; 49(2):482-90. PubMed ID: 19177589
[TBL] [Abstract][Full Text] [Related]
24. Lipid desaturation-associated endoplasmic reticulum stress regulates MYCN gene expression in hepatocellular carcinoma cells.
Qin XY; Su T; Yu W; Kojima S
Cell Death Dis; 2020 Jan; 11(1):66. PubMed ID: 31988297
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of BRD4 suppresses tumor growth in prostate cancer via the enhancement of FOXO1 expression.
Tan Y; Wang L; Du Y; Liu X; Chen Z; Weng X; Guo J; Chen H; Wang M; Wang X
Int J Oncol; 2018 Dec; 53(6):2503-2517. PubMed ID: 30272279
[TBL] [Abstract][Full Text] [Related]
26. TBX2 is a neuroblastoma core regulatory circuitry component enhancing MYCN/FOXM1 reactivation of DREAM targets.
Decaesteker B; Denecker G; Van Neste C; Dolman EM; Van Loocke W; Gartlgruber M; Nunes C; De Vloed F; Depuydt P; Verboom K; Rombaut D; Loontiens S; De Wyn J; Kholosy WM; Koopmans B; Essing AHW; Herrmann C; Dreidax D; Durinck K; Deforce D; Van Nieuwerburgh F; Henssen A; Versteeg R; Boeva V; Schleiermacher G; van Nes J; Mestdagh P; Vanhauwaert S; Schulte JH; Westermann F; Molenaar JJ; De Preter K; Speleman F
Nat Commun; 2018 Nov; 9(1):4866. PubMed ID: 30451831
[TBL] [Abstract][Full Text] [Related]
27. NCYM is upregulated by lncUSMycN and modulates N-Myc expression.
Liu PY; Atmadibrata B; Mondal S; Tee AE; Liu T
Int J Oncol; 2016 Dec; 49(6):2464-2470. PubMed ID: 27748806
[TBL] [Abstract][Full Text] [Related]
28. Targeting LRH‑1 in hepatoblastoma cell lines causes decreased proliferation.
Jin J; Jin J; Woodfield SE; Patel RH; Jin NG; Shi Y; Liu B; Sun W; Chen X; Yu Y; Vasudevan SA
Oncol Rep; 2019 Jan; 41(1):143-153. PubMed ID: 30320362
[TBL] [Abstract][Full Text] [Related]
29. MDM4 inhibition: a novel therapeutic strategy to reactivate p53 in hepatoblastoma.
Woodfield SE; Shi Y; Patel RH; Chen Z; Shah AP; Srivastava RK; Whitlock RS; Ibarra AM; Larson SR; Sarabia SF; Badachhape A; Starosolski Z; Ghaghada KB; Sumazin P; Annis DA; López-Terrada D; Vasudevan SA
Sci Rep; 2021 Feb; 11(1):2967. PubMed ID: 33536467
[TBL] [Abstract][Full Text] [Related]
30. Epigenetic reader BRD4 inhibition as a therapeutic strategy to suppress E2F2-cell cycle regulation circuit in liver cancer.
Hong SH; Eun JW; Choi SK; Shen Q; Choi WS; Han JW; Nam SW; You JS
Oncotarget; 2016 May; 7(22):32628-40. PubMed ID: 27081696
[TBL] [Abstract][Full Text] [Related]
31. Antimyeloma activity of bromodomain inhibitors on the human myeloma cell line U266 by downregulation of MYCL.
Suzuki K; Yamamoto K; Arakawa Y; Yamada H; Aiba K; Kitagawa M
Anticancer Drugs; 2016 Sep; 27(8):756-65. PubMed ID: 27276402
[TBL] [Abstract][Full Text] [Related]
32. Suppression of BRD4 inhibits human hepatocellular carcinoma by repressing MYC and enhancing BIM expression.
Li GQ; Guo WZ; Zhang Y; Seng JJ; Zhang HP; Ma XX; Zhang G; Li J; Yan B; Tang HW; Li SS; Wang LD; Zhang SJ
Oncotarget; 2016 Jan; 7(3):2462-74. PubMed ID: 26575167
[TBL] [Abstract][Full Text] [Related]
33. Primary malignant epithelial tumors of the liver in children: a study of DNA content and oncogene expression.
Zerbini MC; Sredni ST; Grier H; Cristofani LM; Latorre MR; Hollister KA; Alves VA; Weinberg DS; Perez-Atayde AR
Pediatr Dev Pathol; 1998; 1(4):270-80. PubMed ID: 10463288
[TBL] [Abstract][Full Text] [Related]
34. Dual BRD4 and AURKA Inhibition Is Synergistic against MYCN-Amplified and Nonamplified Neuroblastoma.
Felgenhauer J; Tomino L; Selich-Anderson J; Bopp E; Shah N
Neoplasia; 2018 Oct; 20(10):965-974. PubMed ID: 30153557
[TBL] [Abstract][Full Text] [Related]
35. MYCL is a target of a BET bromodomain inhibitor, JQ1, on growth suppression efficacy in small cell lung cancer cells.
Kato F; Fiorentino FP; Alibés A; Perucho M; Sánchez-Céspedes M; Kohno T; Yokota J
Oncotarget; 2016 Nov; 7(47):77378-77388. PubMed ID: 27764802
[TBL] [Abstract][Full Text] [Related]
36. Molecular and in vivo characterization of cancer-propagating cells derived from MYCN-dependent medulloblastoma.
Ahmad Z; Jasnos L; Gil V; Howell L; Hallsworth A; Petrie K; Sawado T; Chesler L
PLoS One; 2015; 10(3):e0119834. PubMed ID: 25785590
[TBL] [Abstract][Full Text] [Related]
37. Targeting MYC as a Therapeutic Intervention for Anaplastic Thyroid Cancer.
Enomoto K; Zhu X; Park S; Zhao L; Zhu YJ; Willingham MC; Qi J; Copland JA; Meltzer P; Cheng SY
J Clin Endocrinol Metab; 2017 Jul; 102(7):2268-2280. PubMed ID: 28368473
[TBL] [Abstract][Full Text] [Related]
38. Genetic and epigenetic basis of hepatoblastoma diversity.
Nagae G; Yamamoto S; Fujita M; Fujita T; Nonaka A; Umeda T; Fukuda S; Tatsuno K; Maejima K; Hayashi A; Kurihara S; Kojima M; Hishiki T; Watanabe K; Ida K; Yano M; Hiyama Y; Tanaka Y; Inoue T; Ueda H; Nakagawa H; Aburatani H; Hiyama E
Nat Commun; 2021 Sep; 12(1):5423. PubMed ID: 34538872
[TBL] [Abstract][Full Text] [Related]
39. Overexpression of MYCN promotes proliferation of non-small cell lung cancer.
Liu K; Wang S; Liu Y; Gu J; Gu S; Xu Z; Zhang R; Wang Z; Ma H; Chen Y; Ji L
Tumour Biol; 2016 Sep; 37(9):12855-12866. PubMed ID: 27449038
[TBL] [Abstract][Full Text] [Related]
40. Expression of NLRR3 orphan receptor gene is negatively regulated by MYCN and Miz-1, and its downregulation is associated with unfavorable outcome in neuroblastoma.
Akter J; Takatori A; Hossain MS; Ozaki T; Nakazawa A; Ohira M; Suenaga Y; Nakagawara A
Clin Cancer Res; 2011 Nov; 17(21):6681-92. PubMed ID: 21908575
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]